EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSBGRG00000010413
Gene Symbol: SCN5A
1 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSBGRG00000023014
Gene Symbol: SCN7A
1 Cross references
85 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSBGRG00000005468
Gene Symbol: SCN8A
1 Cross references
276 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSBGRG00000022714
Gene Symbol: SCN9A
1 Cross references
109 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSBGRG00000004025
Gene Symbol: SLC10A2
1 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSBGRG00000019173
Gene Symbol: SLC18A2
1 Cross references
222 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSBGRG00000007719
Gene Symbol: SLC29A1
1 Cross references
280 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSBGRG00000019426
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSBGRG00000018961
Gene Symbol: SLC5A2
1 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSBGRG00000025174
Gene Symbol: SLC6A1
1 Cross references
281 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSBGRG00000022943
Gene Symbol: SLC6A2
1 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSBGRG00000008417
Gene Symbol: SLC6A3
1 Cross references
166 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).